Summit Therapeutics

Summit Therapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Summit Therapeutics (SMMT) as of Nov 22, 2026 is -210.99 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -88.74 M USD — a change of 137.78% (lower).

EBITDA

-210.99 MUSD

YoY

137.78%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Summit Therapeutics is 2024 -210.99 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Summit Therapeutics was 2023 -88.74 M USD. It decreases by 137.78% lower compared to the previous year.

The Summit Therapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-27.77 M USD
Jan 1, 2018
12.39 M USD
Jan 1, 2019
-26.47 M USD
Jan 1, 2020
-51.03 M USD
Jan 1, 2021
-85.17 M USD
Jan 1, 2022
-62.71 M USD
Jan 1, 2023
-88.74 M USD
Jan 1, 2024
-210.99 M USD
The Summit Therapeutics EBITDA history
YEAREBITDAYoY
-210.99 MUSD+137.78%
-88.74 MUSD+41.50%
-62.71 MUSD-26.37%
-85.17 MUSD+66.90%
-51.03 MUSD+92.78%
-26.47 MUSD-313.64%
12.39 MUSD-144.62%
-27.77 MUSD+14.47%
-24.26 MUSD+16.63%
-20.80 MUSD+62.88%
-12.77 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Summit Therapeutics Stock analysis

What does Summit Therapeutics do? Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK. Summit Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Summit Therapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Summit Therapeutics is -210.99 M USD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Summit Therapeutics changed from -88.74 M USD to -210.99 M USD, representing a 137.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Summit Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Summit Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Summit Therapeutics

All Key Metrics — Summit Therapeutics